Global iPSC-Derived Natural Killer Cells Market Growth 2026-2032
The global iPSC-Derived Natural Killer Cells market size is predicted to grow from US$ 161 million in 2025 to US$ 1147 million in 2032; it is expected to grow at a CAGR of 32.2% from 2026 to 2032.
iPSC-Derived Natural Killer (NK) Cells refer to NK-like immune effector cells generated from induced pluripotent stem cells (iPSCs) through sequential processes including hematopoietic differentiation, NK cell maturation, expansion, purification, and quality control. These cells can be applied in cancer immunotherapy, B-cell depletion research for autoimmune diseases, infectious disease modeling, and cell therapy manufacturing process development. Key advantages include a standardized cell source, strong batch-to-batch consistency, and high amenability to multi-gene engineering at the iPSC stage, such as CAR insertion, CD16 enhancement, IL-15 expression, and immune-evasion modifications. These cells also support cryopreserved off-the-shelf production. The product category is currently mainly positioned in research-use products, CDMO process platforms, and clinical-stage therapeutic candidates. The overall gross margin is approximately 60%.
The evolution of cancer immunotherapy from autologous CAR-T toward allogeneic, off-the-shelf, and repeat-dose cell therapies is driving iPSC-derived NK cells to become a key next-generation modality. Their core value lies in enabling scalable production from a single master cell bank, thereby reducing donor variability and manufacturing scheduling constraints. In addition, iPSC-derived NK cells can be combined with monoclonal antibodies, bispecific or multispecific NK cell engagers, CAR constructs, and other immune-modulating strategies, enabling applications across hematologic malignancies, solid tumors, and B-cell–mediated autoimmune diseases.
Competitive dynamics are shifting from basic NK cell generation toward advanced cell engineering design, GMP-scale manufacturing, post-thaw functional activity, and batch consistency control. Leading companies typically introduce multi-gene engineering at the iPSC stage, followed by closed-system suspension culture, automated differentiation processes, and standardized quality control to improve manufacturability. In the near term, commercial value is concentrated in clinical-grade cell banks, process development services, CDMO manufacturing, and clinical trial supply. Long-term success depends on demonstrating durable efficacy, safety, and improved tumor infiltration capability, particularly in solid tumor indications.
North America remains the dominant region for clinical translation and capital investment, while Japan, Australia, and China are advancing rapidly in iPSC cell banking, regulatory exploration, and domestic clinical programs. Key uncertainties include long-term safety, residual undifferentiated iPSC control, immune rejection risk, scalability costs, and regulatory approval pathways. If engineering strategies and manufacturing economics continue to improve, iPSC-derived NK cells are expected to establish a differentiated position within the allogeneic cell therapy landscape.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “iPSC-Derived Natural Killer Cells Industry Forecast” looks at past sales and reviews total world iPSC-Derived Natural Killer Cells sales in 2025, providing a comprehensive analysis by region and market sector of projected iPSC-Derived Natural Killer Cells sales for 2026 through 2032. With iPSC-Derived Natural Killer Cells sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC-Derived Natural Killer Cells industry.
This Insight Report provides a comprehensive analysis of the global iPSC-Derived Natural Killer Cells landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on iPSC-Derived Natural Killer Cells portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC-Derived Natural Killer Cells market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC-Derived Natural Killer Cells and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC-Derived Natural Killer Cells.
This report presents a comprehensive overview, market shares, and growth opportunities of iPSC-Derived Natural Killer Cells market by product type, application, key manufacturers and key regions and countries.
iPSC-Derived Natural Killer (NK) Cells refer to NK-like immune effector cells generated from induced pluripotent stem cells (iPSCs) through sequential processes including hematopoietic differentiation, NK cell maturation, expansion, purification, and quality control. These cells can be applied in cancer immunotherapy, B-cell depletion research for autoimmune diseases, infectious disease modeling, and cell therapy manufacturing process development. Key advantages include a standardized cell source, strong batch-to-batch consistency, and high amenability to multi-gene engineering at the iPSC stage, such as CAR insertion, CD16 enhancement, IL-15 expression, and immune-evasion modifications. These cells also support cryopreserved off-the-shelf production. The product category is currently mainly positioned in research-use products, CDMO process platforms, and clinical-stage therapeutic candidates. The overall gross margin is approximately 60%.
The evolution of cancer immunotherapy from autologous CAR-T toward allogeneic, off-the-shelf, and repeat-dose cell therapies is driving iPSC-derived NK cells to become a key next-generation modality. Their core value lies in enabling scalable production from a single master cell bank, thereby reducing donor variability and manufacturing scheduling constraints. In addition, iPSC-derived NK cells can be combined with monoclonal antibodies, bispecific or multispecific NK cell engagers, CAR constructs, and other immune-modulating strategies, enabling applications across hematologic malignancies, solid tumors, and B-cell–mediated autoimmune diseases.
Competitive dynamics are shifting from basic NK cell generation toward advanced cell engineering design, GMP-scale manufacturing, post-thaw functional activity, and batch consistency control. Leading companies typically introduce multi-gene engineering at the iPSC stage, followed by closed-system suspension culture, automated differentiation processes, and standardized quality control to improve manufacturability. In the near term, commercial value is concentrated in clinical-grade cell banks, process development services, CDMO manufacturing, and clinical trial supply. Long-term success depends on demonstrating durable efficacy, safety, and improved tumor infiltration capability, particularly in solid tumor indications.
North America remains the dominant region for clinical translation and capital investment, while Japan, Australia, and China are advancing rapidly in iPSC cell banking, regulatory exploration, and domestic clinical programs. Key uncertainties include long-term safety, residual undifferentiated iPSC control, immune rejection risk, scalability costs, and regulatory approval pathways. If engineering strategies and manufacturing economics continue to improve, iPSC-derived NK cells are expected to establish a differentiated position within the allogeneic cell therapy landscape.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “iPSC-Derived Natural Killer Cells Industry Forecast” looks at past sales and reviews total world iPSC-Derived Natural Killer Cells sales in 2025, providing a comprehensive analysis by region and market sector of projected iPSC-Derived Natural Killer Cells sales for 2026 through 2032. With iPSC-Derived Natural Killer Cells sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC-Derived Natural Killer Cells industry.
This Insight Report provides a comprehensive analysis of the global iPSC-Derived Natural Killer Cells landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on iPSC-Derived Natural Killer Cells portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC-Derived Natural Killer Cells market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC-Derived Natural Killer Cells and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC-Derived Natural Killer Cells.
This report presents a comprehensive overview, market shares, and growth opportunities of iPSC-Derived Natural Killer Cells market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Non-Engineered iPSC-Derived NK Cells
- CAR-Engineered iPSC-Derived NK Cells
- CD16-Enhanced iPSC-Derived NK Cells
- Immune-Evasive iPSC-Derived NK Cells
- Multi-Functional iPSC-Derived NK Cells
Segmentation by Cell Source Strategy:
- Healthy Donor iPSC Line
- GMP Master iPSC Bank
- Gene-Edited Universal iPSC Line
- HLA-Matched iPSC Bank
- Patient-Specific iPSC Line
Segmentation by Therapeutic Indication:
- Hematologic Malignancies
- Solid Tumors
- Autoimmune Diseases
- Infectious Diseases
- Inflammation and Tissue Repair
- Other Research Uses
Segmentation by Development and Delivery Format:
- Research-Use Cell Product
- Preclinical Candidate
- Clinical-Grade Drug Product
- CDMO Manufacturing Service
- Cell Bank and Starting Material
Segmentation by Application:
- Cancer Immunotherapy
- Autoimmune Disease Therapy
- Infectious Disease Research
- Drug Screening and Mechanism Studies
- Cell Therapy Process Development
- Other Applications
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Fate Therapeutics
- Century Therapeutics
- Cartherics
- Nuwacell Biotech
- HebeCell
- Healios
- Cytovia Therapeutics
- Shoreline Biosciences
- Applied StemCell
- Cellistic
Key Questions Addressed in this Report
- What is the 10-year outlook for the global iPSC-Derived Natural Killer Cells market?
- What factors are driving iPSC-Derived Natural Killer Cells market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do iPSC-Derived Natural Killer Cells market opportunities vary by end market size?
- How does iPSC-Derived Natural Killer Cells break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global iPSC-Derived Natural Killer Cells Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for iPSC-Derived Natural Killer Cells by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for iPSC-Derived Natural Killer Cells by Country/Region, 2021, 2025 & 2032
2.2 iPSC-Derived Natural Killer Cells Segment by Type
2.2.1 Non-Engineered iPSC-Derived NK Cells
2.2.2 CAR-Engineered iPSC-Derived NK Cells
2.2.3 CD16-Enhanced iPSC-Derived NK Cells
2.2.4 Immune-Evasive iPSC-Derived NK Cells
2.2.5 Multi-Functional iPSC-Derived NK Cells
2.2.6 iPSC-Derived Natural Killer Cells Sales by Type
2.2.6.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
2.2.6.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global iPSC-Derived Natural Killer Cells Sale Price by Type (2021-2026)
2.3 iPSC-Derived Natural Killer Cells Segment by Cell Source Strategy
2.3.1 Healthy Donor iPSC Line
2.3.2 GMP Master iPSC Bank
2.3.3 Gene-Edited Universal iPSC Line
2.3.4 HLA-Matched iPSC Bank
2.3.5 Patient-Specific iPSC Line
2.3.6 iPSC-Derived Natural Killer Cells Sales by Cell Source Strategy
2.3.6.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Cell Source Strategy (2021-2026)
2.3.6.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Cell Source Strategy (2021-2026)
2.3.6.3 Global iPSC-Derived Natural Killer Cells Sale Price by Cell Source Strategy (2021-2026)
2.4 iPSC-Derived Natural Killer Cells Segment by Therapeutic Indication
2.4.1 Hematologic Malignancies
2.4.2 Solid Tumors
2.4.3 Autoimmune Diseases
2.4.4 Infectious Diseases
2.4.5 Inflammation and Tissue Repair
2.4.6 Other Research Uses
2.4.7 iPSC-Derived Natural Killer Cells Sales by Therapeutic Indication
2.4.7.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Therapeutic Indication (2021-2026)
2.4.7.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Therapeutic Indication (2021-2026)
2.4.7.3 Global iPSC-Derived Natural Killer Cells Sale Price by Therapeutic Indication (2021-2026)
2.5 iPSC-Derived Natural Killer Cells Segment by Development and Delivery Format
2.5.1 Research-Use Cell Product
2.5.2 Preclinical Candidate
2.5.3 Clinical-Grade Drug Product
2.5.4 CDMO Manufacturing Service
2.5.5 Cell Bank and Starting Material
2.5.6 iPSC-Derived Natural Killer Cells Sales by Development and Delivery Format
2.5.6.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Development and Delivery Format (2021-2026)
2.5.6.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Development and Delivery Format (2021-2026)
2.5.6.3 Global iPSC-Derived Natural Killer Cells Sale Price by Development and Delivery Format (2021-2026)
2.6 iPSC-Derived Natural Killer Cells Segment by Application
2.6.1 Cancer Immunotherapy
2.6.2 Autoimmune Disease Therapy
2.6.3 Infectious Disease Research
2.6.4 Drug Screening and Mechanism Studies
2.6.5 Cell Therapy Process Development
2.6.6 Other Applications
2.6.7 iPSC-Derived Natural Killer Cells Sales by Application
2.6.7.1 Global iPSC-Derived Natural Killer Cells Sale Market Share by Application (2021-2026)
2.6.7.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Application (2021-2026)
2.6.7.3 Global iPSC-Derived Natural Killer Cells Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global iPSC-Derived Natural Killer Cells Breakdown Data by Company
3.1.1 Global iPSC-Derived Natural Killer Cells Annual Sales by Company (2021-2026)
3.1.2 Global iPSC-Derived Natural Killer Cells Sales Market Share by Company (2021-2026)
3.2 Global iPSC-Derived Natural Killer Cells Annual Revenue by Company (2021-2026)
3.2.1 Global iPSC-Derived Natural Killer Cells Revenue by Company (2021-2026)
3.2.2 Global iPSC-Derived Natural Killer Cells Revenue Market Share by Company (2021-2026)
3.3 Global iPSC-Derived Natural Killer Cells Sale Price by Company
3.4 Key Manufacturers iPSC-Derived Natural Killer Cells Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers iPSC-Derived Natural Killer Cells Product Location Distribution
3.4.2 Players iPSC-Derived Natural Killer Cells Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IPSC-DERIVED NATURAL KILLER CELLS BY GEOGRAPHIC REGION
4.1 World Historic iPSC-Derived Natural Killer Cells Market Size by Geographic Region (2021-2026)
4.1.1 Global iPSC-Derived Natural Killer Cells Annual Sales by Geographic Region (2021-2026)
4.1.2 Global iPSC-Derived Natural Killer Cells Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic iPSC-Derived Natural Killer Cells Market Size by Country/Region (2021-2026)
4.2.1 Global iPSC-Derived Natural Killer Cells Annual Sales by Country/Region (2021-2026)
4.2.2 Global iPSC-Derived Natural Killer Cells Annual Revenue by Country/Region (2021-2026)
4.3 Americas iPSC-Derived Natural Killer Cells Sales Growth
4.4 APAC iPSC-Derived Natural Killer Cells Sales Growth
4.5 Europe iPSC-Derived Natural Killer Cells Sales Growth
4.6 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Growth
5 AMERICAS
5.1 Americas iPSC-Derived Natural Killer Cells Sales by Country
5.1.1 Americas iPSC-Derived Natural Killer Cells Sales by Country (2021-2026)
5.1.2 Americas iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026)
5.2 Americas iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
5.3 Americas iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC iPSC-Derived Natural Killer Cells Sales by Region
6.1.1 APAC iPSC-Derived Natural Killer Cells Sales by Region (2021-2026)
6.1.2 APAC iPSC-Derived Natural Killer Cells Revenue by Region (2021-2026)
6.2 APAC iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
6.3 APAC iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe iPSC-Derived Natural Killer Cells by Country
7.1.1 Europe iPSC-Derived Natural Killer Cells Sales by Country (2021-2026)
7.1.2 Europe iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026)
7.2 Europe iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
7.3 Europe iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa iPSC-Derived Natural Killer Cells by Country
8.1.1 Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Country (2021-2026)
8.1.2 Middle East & Africa iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026)
8.2 Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
8.3 Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of iPSC-Derived Natural Killer Cells
10.3 Manufacturing Process Analysis of iPSC-Derived Natural Killer Cells
10.4 Industry Chain Structure of iPSC-Derived Natural Killer Cells
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 iPSC-Derived Natural Killer Cells Distributors
11.3 iPSC-Derived Natural Killer Cells Customer
12 WORLD FORECAST REVIEW FOR IPSC-DERIVED NATURAL KILLER CELLS BY GEOGRAPHIC REGION
12.1 Global iPSC-Derived Natural Killer Cells Market Size Forecast by Region
12.1.1 Global iPSC-Derived Natural Killer Cells Forecast by Region (2027-2032)
12.1.2 Global iPSC-Derived Natural Killer Cells Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global iPSC-Derived Natural Killer Cells Forecast by Type (2027-2032)
12.7 Global iPSC-Derived Natural Killer Cells Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Fate Therapeutics
13.1.1 Fate Therapeutics Company Information
13.1.2 Fate Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.1.3 Fate Therapeutics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Fate Therapeutics Main Business Overview
13.1.5 Fate Therapeutics Latest Developments
13.2 Century Therapeutics
13.2.1 Century Therapeutics Company Information
13.2.2 Century Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.2.3 Century Therapeutics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Century Therapeutics Main Business Overview
13.2.5 Century Therapeutics Latest Developments
13.3 Cartherics
13.3.1 Cartherics Company Information
13.3.2 Cartherics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.3.3 Cartherics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Cartherics Main Business Overview
13.3.5 Cartherics Latest Developments
13.4 Nuwacell Biotech
13.4.1 Nuwacell Biotech Company Information
13.4.2 Nuwacell Biotech iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.4.3 Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Nuwacell Biotech Main Business Overview
13.4.5 Nuwacell Biotech Latest Developments
13.5 HebeCell
13.5.1 HebeCell Company Information
13.5.2 HebeCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.5.3 HebeCell iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 HebeCell Main Business Overview
13.5.5 HebeCell Latest Developments
13.6 Healios
13.6.1 Healios Company Information
13.6.2 Healios iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.6.3 Healios iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Healios Main Business Overview
13.6.5 Healios Latest Developments
13.7 Cytovia Therapeutics
13.7.1 Cytovia Therapeutics Company Information
13.7.2 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.7.3 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Cytovia Therapeutics Main Business Overview
13.7.5 Cytovia Therapeutics Latest Developments
13.8 Shoreline Biosciences
13.8.1 Shoreline Biosciences Company Information
13.8.2 Shoreline Biosciences iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.8.3 Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Shoreline Biosciences Main Business Overview
13.8.5 Shoreline Biosciences Latest Developments
13.9 Applied StemCell
13.9.1 Applied StemCell Company Information
13.9.2 Applied StemCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.9.3 Applied StemCell iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Applied StemCell Main Business Overview
13.9.5 Applied StemCell Latest Developments
13.10 Cellistic
13.10.1 Cellistic Company Information
13.10.2 Cellistic iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.10.3 Cellistic iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Cellistic Main Business Overview
13.10.5 Cellistic Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global iPSC-Derived Natural Killer Cells Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for iPSC-Derived Natural Killer Cells by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for iPSC-Derived Natural Killer Cells by Country/Region, 2021, 2025 & 2032
2.2 iPSC-Derived Natural Killer Cells Segment by Type
2.2.1 Non-Engineered iPSC-Derived NK Cells
2.2.2 CAR-Engineered iPSC-Derived NK Cells
2.2.3 CD16-Enhanced iPSC-Derived NK Cells
2.2.4 Immune-Evasive iPSC-Derived NK Cells
2.2.5 Multi-Functional iPSC-Derived NK Cells
2.2.6 iPSC-Derived Natural Killer Cells Sales by Type
2.2.6.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
2.2.6.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global iPSC-Derived Natural Killer Cells Sale Price by Type (2021-2026)
2.3 iPSC-Derived Natural Killer Cells Segment by Cell Source Strategy
2.3.1 Healthy Donor iPSC Line
2.3.2 GMP Master iPSC Bank
2.3.3 Gene-Edited Universal iPSC Line
2.3.4 HLA-Matched iPSC Bank
2.3.5 Patient-Specific iPSC Line
2.3.6 iPSC-Derived Natural Killer Cells Sales by Cell Source Strategy
2.3.6.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Cell Source Strategy (2021-2026)
2.3.6.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Cell Source Strategy (2021-2026)
2.3.6.3 Global iPSC-Derived Natural Killer Cells Sale Price by Cell Source Strategy (2021-2026)
2.4 iPSC-Derived Natural Killer Cells Segment by Therapeutic Indication
2.4.1 Hematologic Malignancies
2.4.2 Solid Tumors
2.4.3 Autoimmune Diseases
2.4.4 Infectious Diseases
2.4.5 Inflammation and Tissue Repair
2.4.6 Other Research Uses
2.4.7 iPSC-Derived Natural Killer Cells Sales by Therapeutic Indication
2.4.7.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Therapeutic Indication (2021-2026)
2.4.7.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Therapeutic Indication (2021-2026)
2.4.7.3 Global iPSC-Derived Natural Killer Cells Sale Price by Therapeutic Indication (2021-2026)
2.5 iPSC-Derived Natural Killer Cells Segment by Development and Delivery Format
2.5.1 Research-Use Cell Product
2.5.2 Preclinical Candidate
2.5.3 Clinical-Grade Drug Product
2.5.4 CDMO Manufacturing Service
2.5.5 Cell Bank and Starting Material
2.5.6 iPSC-Derived Natural Killer Cells Sales by Development and Delivery Format
2.5.6.1 Global iPSC-Derived Natural Killer Cells Sales Market Share by Development and Delivery Format (2021-2026)
2.5.6.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Development and Delivery Format (2021-2026)
2.5.6.3 Global iPSC-Derived Natural Killer Cells Sale Price by Development and Delivery Format (2021-2026)
2.6 iPSC-Derived Natural Killer Cells Segment by Application
2.6.1 Cancer Immunotherapy
2.6.2 Autoimmune Disease Therapy
2.6.3 Infectious Disease Research
2.6.4 Drug Screening and Mechanism Studies
2.6.5 Cell Therapy Process Development
2.6.6 Other Applications
2.6.7 iPSC-Derived Natural Killer Cells Sales by Application
2.6.7.1 Global iPSC-Derived Natural Killer Cells Sale Market Share by Application (2021-2026)
2.6.7.2 Global iPSC-Derived Natural Killer Cells Revenue and Market Share by Application (2021-2026)
2.6.7.3 Global iPSC-Derived Natural Killer Cells Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global iPSC-Derived Natural Killer Cells Breakdown Data by Company
3.1.1 Global iPSC-Derived Natural Killer Cells Annual Sales by Company (2021-2026)
3.1.2 Global iPSC-Derived Natural Killer Cells Sales Market Share by Company (2021-2026)
3.2 Global iPSC-Derived Natural Killer Cells Annual Revenue by Company (2021-2026)
3.2.1 Global iPSC-Derived Natural Killer Cells Revenue by Company (2021-2026)
3.2.2 Global iPSC-Derived Natural Killer Cells Revenue Market Share by Company (2021-2026)
3.3 Global iPSC-Derived Natural Killer Cells Sale Price by Company
3.4 Key Manufacturers iPSC-Derived Natural Killer Cells Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers iPSC-Derived Natural Killer Cells Product Location Distribution
3.4.2 Players iPSC-Derived Natural Killer Cells Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IPSC-DERIVED NATURAL KILLER CELLS BY GEOGRAPHIC REGION
4.1 World Historic iPSC-Derived Natural Killer Cells Market Size by Geographic Region (2021-2026)
4.1.1 Global iPSC-Derived Natural Killer Cells Annual Sales by Geographic Region (2021-2026)
4.1.2 Global iPSC-Derived Natural Killer Cells Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic iPSC-Derived Natural Killer Cells Market Size by Country/Region (2021-2026)
4.2.1 Global iPSC-Derived Natural Killer Cells Annual Sales by Country/Region (2021-2026)
4.2.2 Global iPSC-Derived Natural Killer Cells Annual Revenue by Country/Region (2021-2026)
4.3 Americas iPSC-Derived Natural Killer Cells Sales Growth
4.4 APAC iPSC-Derived Natural Killer Cells Sales Growth
4.5 Europe iPSC-Derived Natural Killer Cells Sales Growth
4.6 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Growth
5 AMERICAS
5.1 Americas iPSC-Derived Natural Killer Cells Sales by Country
5.1.1 Americas iPSC-Derived Natural Killer Cells Sales by Country (2021-2026)
5.1.2 Americas iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026)
5.2 Americas iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
5.3 Americas iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC iPSC-Derived Natural Killer Cells Sales by Region
6.1.1 APAC iPSC-Derived Natural Killer Cells Sales by Region (2021-2026)
6.1.2 APAC iPSC-Derived Natural Killer Cells Revenue by Region (2021-2026)
6.2 APAC iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
6.3 APAC iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe iPSC-Derived Natural Killer Cells by Country
7.1.1 Europe iPSC-Derived Natural Killer Cells Sales by Country (2021-2026)
7.1.2 Europe iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026)
7.2 Europe iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
7.3 Europe iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa iPSC-Derived Natural Killer Cells by Country
8.1.1 Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Country (2021-2026)
8.1.2 Middle East & Africa iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026)
8.2 Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Type (2021-2026)
8.3 Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of iPSC-Derived Natural Killer Cells
10.3 Manufacturing Process Analysis of iPSC-Derived Natural Killer Cells
10.4 Industry Chain Structure of iPSC-Derived Natural Killer Cells
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 iPSC-Derived Natural Killer Cells Distributors
11.3 iPSC-Derived Natural Killer Cells Customer
12 WORLD FORECAST REVIEW FOR IPSC-DERIVED NATURAL KILLER CELLS BY GEOGRAPHIC REGION
12.1 Global iPSC-Derived Natural Killer Cells Market Size Forecast by Region
12.1.1 Global iPSC-Derived Natural Killer Cells Forecast by Region (2027-2032)
12.1.2 Global iPSC-Derived Natural Killer Cells Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global iPSC-Derived Natural Killer Cells Forecast by Type (2027-2032)
12.7 Global iPSC-Derived Natural Killer Cells Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Fate Therapeutics
13.1.1 Fate Therapeutics Company Information
13.1.2 Fate Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.1.3 Fate Therapeutics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Fate Therapeutics Main Business Overview
13.1.5 Fate Therapeutics Latest Developments
13.2 Century Therapeutics
13.2.1 Century Therapeutics Company Information
13.2.2 Century Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.2.3 Century Therapeutics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Century Therapeutics Main Business Overview
13.2.5 Century Therapeutics Latest Developments
13.3 Cartherics
13.3.1 Cartherics Company Information
13.3.2 Cartherics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.3.3 Cartherics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Cartherics Main Business Overview
13.3.5 Cartherics Latest Developments
13.4 Nuwacell Biotech
13.4.1 Nuwacell Biotech Company Information
13.4.2 Nuwacell Biotech iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.4.3 Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Nuwacell Biotech Main Business Overview
13.4.5 Nuwacell Biotech Latest Developments
13.5 HebeCell
13.5.1 HebeCell Company Information
13.5.2 HebeCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.5.3 HebeCell iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 HebeCell Main Business Overview
13.5.5 HebeCell Latest Developments
13.6 Healios
13.6.1 Healios Company Information
13.6.2 Healios iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.6.3 Healios iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Healios Main Business Overview
13.6.5 Healios Latest Developments
13.7 Cytovia Therapeutics
13.7.1 Cytovia Therapeutics Company Information
13.7.2 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.7.3 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Cytovia Therapeutics Main Business Overview
13.7.5 Cytovia Therapeutics Latest Developments
13.8 Shoreline Biosciences
13.8.1 Shoreline Biosciences Company Information
13.8.2 Shoreline Biosciences iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.8.3 Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Shoreline Biosciences Main Business Overview
13.8.5 Shoreline Biosciences Latest Developments
13.9 Applied StemCell
13.9.1 Applied StemCell Company Information
13.9.2 Applied StemCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.9.3 Applied StemCell iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Applied StemCell Main Business Overview
13.9.5 Applied StemCell Latest Developments
13.10 Cellistic
13.10.1 Cellistic Company Information
13.10.2 Cellistic iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
13.10.3 Cellistic iPSC-Derived Natural Killer Cells Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Cellistic Main Business Overview
13.10.5 Cellistic Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. iPSC-Derived Natural Killer Cells Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. iPSC-Derived Natural Killer Cells Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Non-Engineered iPSC-Derived NK Cells
Table 4. Major Players of CAR-Engineered iPSC-Derived NK Cells
Table 5. Major Players of CD16-Enhanced iPSC-Derived NK Cells
Table 6. Major Players of Immune-Evasive iPSC-Derived NK Cells
Table 7. Major Players of Multi-Functional iPSC-Derived NK Cells
Table 8. Global iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 9. Global iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Table 10. Global iPSC-Derived Natural Killer Cells Revenue by Type (2021-2026) & ($ million)
Table 11. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Type (2021-2026)
Table 12. Global iPSC-Derived Natural Killer Cells Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Healthy Donor iPSC Line
Table 14. Major Players of GMP Master iPSC Bank
Table 15. Major Players of Gene-Edited Universal iPSC Line
Table 16. Major Players of HLA-Matched iPSC Bank
Table 17. Major Players of Patient-Specific iPSC Line
Table 18. Global iPSC-Derived Natural Killer Cells Sales by Cell Source Strategy (2021-2026) & (K Dose)
Table 19. Global iPSC-Derived Natural Killer Cells Sales Market Share by Cell Source Strategy (2021-2026)
Table 20. Global iPSC-Derived Natural Killer Cells Revenue by Cell Source Strategy (2021-2026) & ($ million)
Table 21. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Cell Source Strategy (2021-2026)
Table 22. Global iPSC-Derived Natural Killer Cells Sale Price by Cell Source Strategy (2021-2026) & (US$/Dose)
Table 23. Major Players of Hematologic Malignancies
Table 24. Major Players of Solid Tumors
Table 25. Major Players of Autoimmune Diseases
Table 26. Major Players of Infectious Diseases
Table 27. Major Players of Inflammation and Tissue Repair
Table 28. Major Players of Other Research Uses
Table 29. Global iPSC-Derived Natural Killer Cells Sales by Therapeutic Indication (2021-2026) & (K Dose)
Table 30. Global iPSC-Derived Natural Killer Cells Sales Market Share by Therapeutic Indication (2021-2026)
Table 31. Global iPSC-Derived Natural Killer Cells Revenue by Therapeutic Indication (2021-2026) & ($ million)
Table 32. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Therapeutic Indication (2021-2026)
Table 33. Global iPSC-Derived Natural Killer Cells Sale Price by Therapeutic Indication (2021-2026) & (US$/Dose)
Table 34. Major Players of Research-Use Cell Product
Table 35. Major Players of Preclinical Candidate
Table 36. Major Players of Clinical-Grade Drug Product
Table 37. Major Players of CDMO Manufacturing Service
Table 38. Major Players of Cell Bank and Starting Material
Table 39. Global iPSC-Derived Natural Killer Cells Sales by Development and Delivery Format (2021-2026) & (K Dose)
Table 40. Global iPSC-Derived Natural Killer Cells Sales Market Share by Development and Delivery Format (2021-2026)
Table 41. Global iPSC-Derived Natural Killer Cells Revenue by Development and Delivery Format (2021-2026) & ($ million)
Table 42. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Development and Delivery Format (2021-2026)
Table 43. Global iPSC-Derived Natural Killer Cells Sale Price by Development and Delivery Format (2021-2026) & (US$/Dose)
Table 44. Global iPSC-Derived Natural Killer Cells Sale by Application (2021-2026) & (K Dose)
Table 45. Global iPSC-Derived Natural Killer Cells Sale Market Share by Application (2021-2026)
Table 46. Global iPSC-Derived Natural Killer Cells Revenue by Application (2021-2026) & ($ million)
Table 47. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application (2021-2026)
Table 48. Global iPSC-Derived Natural Killer Cells Sale Price by Application (2021-2026) & (US$/Dose)
Table 49. Global iPSC-Derived Natural Killer Cells Sales by Company (2021-2026) & (K Dose)
Table 50. Global iPSC-Derived Natural Killer Cells Sales Market Share by Company (2021-2026)
Table 51. Global iPSC-Derived Natural Killer Cells Revenue by Company (2021-2026) & ($ millions)
Table 52. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Company (2021-2026)
Table 53. Global iPSC-Derived Natural Killer Cells Sale Price by Company (2021-2026) & (US$/Dose)
Table 54. Key Manufacturers iPSC-Derived Natural Killer Cells Producing Area Distribution and Sales Area
Table 55. Players iPSC-Derived Natural Killer Cells Products Offered
Table 56. iPSC-Derived Natural Killer Cells Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 57. New Products and Potential Entrants
Table 58. Market M&A Activity & Strategy
Table 59. Global iPSC-Derived Natural Killer Cells Sales by Geographic Region (2021-2026) & (K Dose)
Table 60. Global iPSC-Derived Natural Killer Cells Sales Market Share Geographic Region (2021-2026)
Table 61. Global iPSC-Derived Natural Killer Cells Revenue by Geographic Region (2021-2026) & ($ millions)
Table 62. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Geographic Region (2021-2026)
Table 63. Global iPSC-Derived Natural Killer Cells Sales by Country/Region (2021-2026) & (K Dose)
Table 64. Global iPSC-Derived Natural Killer Cells Sales Market Share by Country/Region (2021-2026)
Table 65. Global iPSC-Derived Natural Killer Cells Revenue by Country/Region (2021-2026) & ($ millions)
Table 66. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Country/Region (2021-2026)
Table 67. Americas iPSC-Derived Natural Killer Cells Sales by Country (2021-2026) & (K Dose)
Table 68. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Country (2021-2026)
Table 69. Americas iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026) & ($ millions)
Table 70. Americas iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 71. Americas iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 72. APAC iPSC-Derived Natural Killer Cells Sales by Region (2021-2026) & (K Dose)
Table 73. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Region (2021-2026)
Table 74. APAC iPSC-Derived Natural Killer Cells Revenue by Region (2021-2026) & ($ millions)
Table 75. APAC iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 76. APAC iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 77. Europe iPSC-Derived Natural Killer Cells Sales by Country (2021-2026) & (K Dose)
Table 78. Europe iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026) & ($ millions)
Table 79. Europe iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 80. Europe iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 81. Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Country (2021-2026) & (K Dose)
Table 82. Middle East & Africa iPSC-Derived Natural Killer Cells Revenue Market Share by Country (2021-2026)
Table 83. Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 84. Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 85. Key Market Drivers & Growth Opportunities of iPSC-Derived Natural Killer Cells
Table 86. Key Market Challenges & Risks of iPSC-Derived Natural Killer Cells
Table 87. Key Industry Trends of iPSC-Derived Natural Killer Cells
Table 88. iPSC-Derived Natural Killer Cells Raw Material
Table 89. Key Suppliers of Raw Materials
Table 90. iPSC-Derived Natural Killer Cells Distributors List
Table 91. iPSC-Derived Natural Killer Cells Customer List
Table 92. Global iPSC-Derived Natural Killer Cells Sales Forecast by Region (2027-2032) & (K Dose)
Table 93. Global iPSC-Derived Natural Killer Cells Revenue Forecast by Region (2027-2032) & ($ millions)
Table 94. Americas iPSC-Derived Natural Killer Cells Sales Forecast by Country (2027-2032) & (K Dose)
Table 95. Americas iPSC-Derived Natural Killer Cells Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 96. APAC iPSC-Derived Natural Killer Cells Sales Forecast by Region (2027-2032) & (K Dose)
Table 97. APAC iPSC-Derived Natural Killer Cells Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 98. Europe iPSC-Derived Natural Killer Cells Sales Forecast by Country (2027-2032) & (K Dose)
Table 99. Europe iPSC-Derived Natural Killer Cells Revenue Forecast by Country (2027-2032) & ($ millions)
Table 100. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Forecast by Country (2027-2032) & (K Dose)
Table 101. Middle East & Africa iPSC-Derived Natural Killer Cells Revenue Forecast by Country (2027-2032) & ($ millions)
Table 102. Global iPSC-Derived Natural Killer Cells Sales Forecast by Type (2027-2032) & (K Dose)
Table 103. Global iPSC-Derived Natural Killer Cells Revenue Forecast by Type (2027-2032) & ($ millions)
Table 104. Global iPSC-Derived Natural Killer Cells Sales Forecast by Application (2027-2032) & (K Dose)
Table 105. Global iPSC-Derived Natural Killer Cells Revenue Forecast by Application (2027-2032) & ($ millions)
Table 106. Fate Therapeutics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 107. Fate Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 108. Fate Therapeutics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 109. Fate Therapeutics Main Business
Table 110. Fate Therapeutics Latest Developments
Table 111. Century Therapeutics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 112. Century Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 113. Century Therapeutics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 114. Century Therapeutics Main Business
Table 115. Century Therapeutics Latest Developments
Table 116. Cartherics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 117. Cartherics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 118. Cartherics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 119. Cartherics Main Business
Table 120. Cartherics Latest Developments
Table 121. Nuwacell Biotech Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 122. Nuwacell Biotech iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 123. Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 124. Nuwacell Biotech Main Business
Table 125. Nuwacell Biotech Latest Developments
Table 126. HebeCell Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 127. HebeCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 128. HebeCell iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 129. HebeCell Main Business
Table 130. HebeCell Latest Developments
Table 131. Healios Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 132. Healios iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 133. Healios iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 134. Healios Main Business
Table 135. Healios Latest Developments
Table 136. Cytovia Therapeutics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 137. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 138. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 139. Cytovia Therapeutics Main Business
Table 140. Cytovia Therapeutics Latest Developments
Table 141. Shoreline Biosciences Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 142. Shoreline Biosciences iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 143. Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 144. Shoreline Biosciences Main Business
Table 145. Shoreline Biosciences Latest Developments
Table 146. Applied StemCell Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 147. Applied StemCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 148. Applied StemCell iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 149. Applied StemCell Main Business
Table 150. Applied StemCell Latest Developments
Table 151. Cellistic Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 152. Cellistic iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 153. Cellistic iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 154. Cellistic Main Business
Table 155. Cellistic Latest Developments
Table 1. iPSC-Derived Natural Killer Cells Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. iPSC-Derived Natural Killer Cells Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Non-Engineered iPSC-Derived NK Cells
Table 4. Major Players of CAR-Engineered iPSC-Derived NK Cells
Table 5. Major Players of CD16-Enhanced iPSC-Derived NK Cells
Table 6. Major Players of Immune-Evasive iPSC-Derived NK Cells
Table 7. Major Players of Multi-Functional iPSC-Derived NK Cells
Table 8. Global iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 9. Global iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Table 10. Global iPSC-Derived Natural Killer Cells Revenue by Type (2021-2026) & ($ million)
Table 11. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Type (2021-2026)
Table 12. Global iPSC-Derived Natural Killer Cells Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Healthy Donor iPSC Line
Table 14. Major Players of GMP Master iPSC Bank
Table 15. Major Players of Gene-Edited Universal iPSC Line
Table 16. Major Players of HLA-Matched iPSC Bank
Table 17. Major Players of Patient-Specific iPSC Line
Table 18. Global iPSC-Derived Natural Killer Cells Sales by Cell Source Strategy (2021-2026) & (K Dose)
Table 19. Global iPSC-Derived Natural Killer Cells Sales Market Share by Cell Source Strategy (2021-2026)
Table 20. Global iPSC-Derived Natural Killer Cells Revenue by Cell Source Strategy (2021-2026) & ($ million)
Table 21. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Cell Source Strategy (2021-2026)
Table 22. Global iPSC-Derived Natural Killer Cells Sale Price by Cell Source Strategy (2021-2026) & (US$/Dose)
Table 23. Major Players of Hematologic Malignancies
Table 24. Major Players of Solid Tumors
Table 25. Major Players of Autoimmune Diseases
Table 26. Major Players of Infectious Diseases
Table 27. Major Players of Inflammation and Tissue Repair
Table 28. Major Players of Other Research Uses
Table 29. Global iPSC-Derived Natural Killer Cells Sales by Therapeutic Indication (2021-2026) & (K Dose)
Table 30. Global iPSC-Derived Natural Killer Cells Sales Market Share by Therapeutic Indication (2021-2026)
Table 31. Global iPSC-Derived Natural Killer Cells Revenue by Therapeutic Indication (2021-2026) & ($ million)
Table 32. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Therapeutic Indication (2021-2026)
Table 33. Global iPSC-Derived Natural Killer Cells Sale Price by Therapeutic Indication (2021-2026) & (US$/Dose)
Table 34. Major Players of Research-Use Cell Product
Table 35. Major Players of Preclinical Candidate
Table 36. Major Players of Clinical-Grade Drug Product
Table 37. Major Players of CDMO Manufacturing Service
Table 38. Major Players of Cell Bank and Starting Material
Table 39. Global iPSC-Derived Natural Killer Cells Sales by Development and Delivery Format (2021-2026) & (K Dose)
Table 40. Global iPSC-Derived Natural Killer Cells Sales Market Share by Development and Delivery Format (2021-2026)
Table 41. Global iPSC-Derived Natural Killer Cells Revenue by Development and Delivery Format (2021-2026) & ($ million)
Table 42. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Development and Delivery Format (2021-2026)
Table 43. Global iPSC-Derived Natural Killer Cells Sale Price by Development and Delivery Format (2021-2026) & (US$/Dose)
Table 44. Global iPSC-Derived Natural Killer Cells Sale by Application (2021-2026) & (K Dose)
Table 45. Global iPSC-Derived Natural Killer Cells Sale Market Share by Application (2021-2026)
Table 46. Global iPSC-Derived Natural Killer Cells Revenue by Application (2021-2026) & ($ million)
Table 47. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application (2021-2026)
Table 48. Global iPSC-Derived Natural Killer Cells Sale Price by Application (2021-2026) & (US$/Dose)
Table 49. Global iPSC-Derived Natural Killer Cells Sales by Company (2021-2026) & (K Dose)
Table 50. Global iPSC-Derived Natural Killer Cells Sales Market Share by Company (2021-2026)
Table 51. Global iPSC-Derived Natural Killer Cells Revenue by Company (2021-2026) & ($ millions)
Table 52. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Company (2021-2026)
Table 53. Global iPSC-Derived Natural Killer Cells Sale Price by Company (2021-2026) & (US$/Dose)
Table 54. Key Manufacturers iPSC-Derived Natural Killer Cells Producing Area Distribution and Sales Area
Table 55. Players iPSC-Derived Natural Killer Cells Products Offered
Table 56. iPSC-Derived Natural Killer Cells Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 57. New Products and Potential Entrants
Table 58. Market M&A Activity & Strategy
Table 59. Global iPSC-Derived Natural Killer Cells Sales by Geographic Region (2021-2026) & (K Dose)
Table 60. Global iPSC-Derived Natural Killer Cells Sales Market Share Geographic Region (2021-2026)
Table 61. Global iPSC-Derived Natural Killer Cells Revenue by Geographic Region (2021-2026) & ($ millions)
Table 62. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Geographic Region (2021-2026)
Table 63. Global iPSC-Derived Natural Killer Cells Sales by Country/Region (2021-2026) & (K Dose)
Table 64. Global iPSC-Derived Natural Killer Cells Sales Market Share by Country/Region (2021-2026)
Table 65. Global iPSC-Derived Natural Killer Cells Revenue by Country/Region (2021-2026) & ($ millions)
Table 66. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Country/Region (2021-2026)
Table 67. Americas iPSC-Derived Natural Killer Cells Sales by Country (2021-2026) & (K Dose)
Table 68. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Country (2021-2026)
Table 69. Americas iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026) & ($ millions)
Table 70. Americas iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 71. Americas iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 72. APAC iPSC-Derived Natural Killer Cells Sales by Region (2021-2026) & (K Dose)
Table 73. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Region (2021-2026)
Table 74. APAC iPSC-Derived Natural Killer Cells Revenue by Region (2021-2026) & ($ millions)
Table 75. APAC iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 76. APAC iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 77. Europe iPSC-Derived Natural Killer Cells Sales by Country (2021-2026) & (K Dose)
Table 78. Europe iPSC-Derived Natural Killer Cells Revenue by Country (2021-2026) & ($ millions)
Table 79. Europe iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 80. Europe iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 81. Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Country (2021-2026) & (K Dose)
Table 82. Middle East & Africa iPSC-Derived Natural Killer Cells Revenue Market Share by Country (2021-2026)
Table 83. Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Type (2021-2026) & (K Dose)
Table 84. Middle East & Africa iPSC-Derived Natural Killer Cells Sales by Application (2021-2026) & (K Dose)
Table 85. Key Market Drivers & Growth Opportunities of iPSC-Derived Natural Killer Cells
Table 86. Key Market Challenges & Risks of iPSC-Derived Natural Killer Cells
Table 87. Key Industry Trends of iPSC-Derived Natural Killer Cells
Table 88. iPSC-Derived Natural Killer Cells Raw Material
Table 89. Key Suppliers of Raw Materials
Table 90. iPSC-Derived Natural Killer Cells Distributors List
Table 91. iPSC-Derived Natural Killer Cells Customer List
Table 92. Global iPSC-Derived Natural Killer Cells Sales Forecast by Region (2027-2032) & (K Dose)
Table 93. Global iPSC-Derived Natural Killer Cells Revenue Forecast by Region (2027-2032) & ($ millions)
Table 94. Americas iPSC-Derived Natural Killer Cells Sales Forecast by Country (2027-2032) & (K Dose)
Table 95. Americas iPSC-Derived Natural Killer Cells Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 96. APAC iPSC-Derived Natural Killer Cells Sales Forecast by Region (2027-2032) & (K Dose)
Table 97. APAC iPSC-Derived Natural Killer Cells Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 98. Europe iPSC-Derived Natural Killer Cells Sales Forecast by Country (2027-2032) & (K Dose)
Table 99. Europe iPSC-Derived Natural Killer Cells Revenue Forecast by Country (2027-2032) & ($ millions)
Table 100. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Forecast by Country (2027-2032) & (K Dose)
Table 101. Middle East & Africa iPSC-Derived Natural Killer Cells Revenue Forecast by Country (2027-2032) & ($ millions)
Table 102. Global iPSC-Derived Natural Killer Cells Sales Forecast by Type (2027-2032) & (K Dose)
Table 103. Global iPSC-Derived Natural Killer Cells Revenue Forecast by Type (2027-2032) & ($ millions)
Table 104. Global iPSC-Derived Natural Killer Cells Sales Forecast by Application (2027-2032) & (K Dose)
Table 105. Global iPSC-Derived Natural Killer Cells Revenue Forecast by Application (2027-2032) & ($ millions)
Table 106. Fate Therapeutics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 107. Fate Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 108. Fate Therapeutics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 109. Fate Therapeutics Main Business
Table 110. Fate Therapeutics Latest Developments
Table 111. Century Therapeutics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 112. Century Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 113. Century Therapeutics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 114. Century Therapeutics Main Business
Table 115. Century Therapeutics Latest Developments
Table 116. Cartherics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 117. Cartherics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 118. Cartherics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 119. Cartherics Main Business
Table 120. Cartherics Latest Developments
Table 121. Nuwacell Biotech Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 122. Nuwacell Biotech iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 123. Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 124. Nuwacell Biotech Main Business
Table 125. Nuwacell Biotech Latest Developments
Table 126. HebeCell Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 127. HebeCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 128. HebeCell iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 129. HebeCell Main Business
Table 130. HebeCell Latest Developments
Table 131. Healios Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 132. Healios iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 133. Healios iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 134. Healios Main Business
Table 135. Healios Latest Developments
Table 136. Cytovia Therapeutics Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 137. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 138. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 139. Cytovia Therapeutics Main Business
Table 140. Cytovia Therapeutics Latest Developments
Table 141. Shoreline Biosciences Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 142. Shoreline Biosciences iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 143. Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 144. Shoreline Biosciences Main Business
Table 145. Shoreline Biosciences Latest Developments
Table 146. Applied StemCell Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 147. Applied StemCell iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 148. Applied StemCell iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 149. Applied StemCell Main Business
Table 150. Applied StemCell Latest Developments
Table 151. Cellistic Basic Information, iPSC-Derived Natural Killer Cells Manufacturing Base, Sales Area and Its Competitors
Table 152. Cellistic iPSC-Derived Natural Killer Cells Product Portfolios and Specifications
Table 153. Cellistic iPSC-Derived Natural Killer Cells Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 154. Cellistic Main Business
Table 155. Cellistic Latest Developments
LIST OF FIGURES
Figure 1. Picture of iPSC-Derived Natural Killer Cells
Figure 2. iPSC-Derived Natural Killer Cells Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global iPSC-Derived Natural Killer Cells Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global iPSC-Derived Natural Killer Cells Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. iPSC-Derived Natural Killer Cells Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. iPSC-Derived Natural Killer Cells Sales Market Share by Country/Region (2025)
Figure 10. iPSC-Derived Natural Killer Cells Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Non-Engineered iPSC-Derived NK Cells
Figure 12. Product Picture of CAR-Engineered iPSC-Derived NK Cells
Figure 13. Product Picture of CD16-Enhanced iPSC-Derived NK Cells
Figure 14. Product Picture of Immune-Evasive iPSC-Derived NK Cells
Figure 15. Product Picture of Multi-Functional iPSC-Derived NK Cells
Figure 16. Global iPSC-Derived Natural Killer Cells Sales Market Share by Type in 2026
Figure 17. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Healthy Donor iPSC Line
Figure 19. Product Picture of GMP Master iPSC Bank
Figure 20. Product Picture of Gene-Edited Universal iPSC Line
Figure 21. Product Picture of HLA-Matched iPSC Bank
Figure 22. Product Picture of Patient-Specific iPSC Line
Figure 23. Global iPSC-Derived Natural Killer Cells Sales Market Share by Cell Source Strategy in 2026
Figure 24. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Cell Source Strategy (2021-2026)
Figure 25. Product Picture of Hematologic Malignancies
Figure 26. Product Picture of Solid Tumors
Figure 27. Product Picture of Autoimmune Diseases
Figure 28. Product Picture of Infectious Diseases
Figure 29. Product Picture of Inflammation and Tissue Repair
Figure 30. Product Picture of Other Research Uses
Figure 31. Global iPSC-Derived Natural Killer Cells Sales Market Share by Therapeutic Indication in 2026
Figure 32. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Therapeutic Indication (2021-2026)
Figure 33. Product Picture of Research-Use Cell Product
Figure 34. Product Picture of Preclinical Candidate
Figure 35. Product Picture of Clinical-Grade Drug Product
Figure 36. Product Picture of CDMO Manufacturing Service
Figure 37. Product Picture of Cell Bank and Starting Material
Figure 38. Global iPSC-Derived Natural Killer Cells Sales Market Share by Development and Delivery Format in 2026
Figure 39. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Development and Delivery Format (2021-2026)
Figure 40. iPSC-Derived Natural Killer Cells Consumed in Cancer Immunotherapy
Figure 41. Global iPSC-Derived Natural Killer Cells Market: Cancer Immunotherapy (2021-2026) & (K Dose)
Figure 42. iPSC-Derived Natural Killer Cells Consumed in Autoimmune Disease Therapy
Figure 43. Global iPSC-Derived Natural Killer Cells Market: Autoimmune Disease Therapy (2021-2026) & (K Dose)
Figure 44. iPSC-Derived Natural Killer Cells Consumed in Infectious Disease Research
Figure 45. Global iPSC-Derived Natural Killer Cells Market: Infectious Disease Research (2021-2026) & (K Dose)
Figure 46. iPSC-Derived Natural Killer Cells Consumed in Drug Screening and Mechanism Studies
Figure 47. Global iPSC-Derived Natural Killer Cells Market: Drug Screening and Mechanism Studies (2021-2026) & (K Dose)
Figure 48. iPSC-Derived Natural Killer Cells Consumed in Cell Therapy Process Development
Figure 49. Global iPSC-Derived Natural Killer Cells Market: Cell Therapy Process Development (2021-2026) & (K Dose)
Figure 50. iPSC-Derived Natural Killer Cells Consumed in Other Applications
Figure 51. Global iPSC-Derived Natural Killer Cells Market: Other Applications (2021-2026) & (K Dose)
Figure 52. Global iPSC-Derived Natural Killer Cells Sale Market Share by Application (2025)
Figure 53. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application in 2025
Figure 54. iPSC-Derived Natural Killer Cells Sales by Company in 2025 (K Dose)
Figure 55. Global iPSC-Derived Natural Killer Cells Sales Market Share by Company in 2025
Figure 56. iPSC-Derived Natural Killer Cells Revenue by Company in 2025 ($ millions)
Figure 57. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Company in 2025
Figure 58. Global iPSC-Derived Natural Killer Cells Sales Market Share by Geographic Region (2021-2026)
Figure 59. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Geographic Region in 2025
Figure 60. Americas iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 61. Americas iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 62. APAC iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 63. APAC iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 64. Europe iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 65. Europe iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 66. Middle East & Africa iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 67. Middle East & Africa iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 68. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Country in 2025
Figure 69. Americas iPSC-Derived Natural Killer Cells Revenue Market Share by Country (2021-2026)
Figure 70. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 71. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 72. United States iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 73. Canada iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 74. Mexico iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 75. Brazil iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 76. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Region in 2025
Figure 77. APAC iPSC-Derived Natural Killer Cells Revenue Market Share by Region (2021-2026)
Figure 78. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 79. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 80. China iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 81. Japan iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 82. South Korea iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 83. Southeast Asia iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 84. India iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 85. Australia iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 86. China Taiwan iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 87. Europe iPSC-Derived Natural Killer Cells Sales Market Share by Country in 2025
Figure 88. Europe iPSC-Derived Natural Killer Cells Revenue Market Share by Country (2021-2026)
Figure 89. Europe iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 90. Europe iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 91. Germany iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 92. France iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 93. UK iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 94. Italy iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 95. Russia iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 96. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Market Share by Country (2021-2026)
Figure 97. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 98. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 99. Egypt iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 100. South Africa iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 101. Israel iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 102. Turkey iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 103. GCC Countries iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 104. Manufacturing Cost Structure Analysis of iPSC-Derived Natural Killer Cells in 2026
Figure 105. Manufacturing Process Analysis of iPSC-Derived Natural Killer Cells
Figure 106. Industry Chain Structure of iPSC-Derived Natural Killer Cells
Figure 107. Channels of Distribution
Figure 108. Global iPSC-Derived Natural Killer Cells Sales Market Forecast by Region (2027-2032)
Figure 109. Global iPSC-Derived Natural Killer Cells Revenue Market Share Forecast by Region (2027-2032)
Figure 110. Global iPSC-Derived Natural Killer Cells Sales Market Share Forecast by Type (2027-2032)
Figure 111. Global iPSC-Derived Natural Killer Cells Revenue Market Share Forecast by Type (2027-2032)
Figure 112. Global iPSC-Derived Natural Killer Cells Sales Market Share Forecast by Application (2027-2032)
Figure 113. Global iPSC-Derived Natural Killer Cells Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of iPSC-Derived Natural Killer Cells
Figure 2. iPSC-Derived Natural Killer Cells Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global iPSC-Derived Natural Killer Cells Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global iPSC-Derived Natural Killer Cells Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. iPSC-Derived Natural Killer Cells Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. iPSC-Derived Natural Killer Cells Sales Market Share by Country/Region (2025)
Figure 10. iPSC-Derived Natural Killer Cells Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Non-Engineered iPSC-Derived NK Cells
Figure 12. Product Picture of CAR-Engineered iPSC-Derived NK Cells
Figure 13. Product Picture of CD16-Enhanced iPSC-Derived NK Cells
Figure 14. Product Picture of Immune-Evasive iPSC-Derived NK Cells
Figure 15. Product Picture of Multi-Functional iPSC-Derived NK Cells
Figure 16. Global iPSC-Derived Natural Killer Cells Sales Market Share by Type in 2026
Figure 17. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Healthy Donor iPSC Line
Figure 19. Product Picture of GMP Master iPSC Bank
Figure 20. Product Picture of Gene-Edited Universal iPSC Line
Figure 21. Product Picture of HLA-Matched iPSC Bank
Figure 22. Product Picture of Patient-Specific iPSC Line
Figure 23. Global iPSC-Derived Natural Killer Cells Sales Market Share by Cell Source Strategy in 2026
Figure 24. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Cell Source Strategy (2021-2026)
Figure 25. Product Picture of Hematologic Malignancies
Figure 26. Product Picture of Solid Tumors
Figure 27. Product Picture of Autoimmune Diseases
Figure 28. Product Picture of Infectious Diseases
Figure 29. Product Picture of Inflammation and Tissue Repair
Figure 30. Product Picture of Other Research Uses
Figure 31. Global iPSC-Derived Natural Killer Cells Sales Market Share by Therapeutic Indication in 2026
Figure 32. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Therapeutic Indication (2021-2026)
Figure 33. Product Picture of Research-Use Cell Product
Figure 34. Product Picture of Preclinical Candidate
Figure 35. Product Picture of Clinical-Grade Drug Product
Figure 36. Product Picture of CDMO Manufacturing Service
Figure 37. Product Picture of Cell Bank and Starting Material
Figure 38. Global iPSC-Derived Natural Killer Cells Sales Market Share by Development and Delivery Format in 2026
Figure 39. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Development and Delivery Format (2021-2026)
Figure 40. iPSC-Derived Natural Killer Cells Consumed in Cancer Immunotherapy
Figure 41. Global iPSC-Derived Natural Killer Cells Market: Cancer Immunotherapy (2021-2026) & (K Dose)
Figure 42. iPSC-Derived Natural Killer Cells Consumed in Autoimmune Disease Therapy
Figure 43. Global iPSC-Derived Natural Killer Cells Market: Autoimmune Disease Therapy (2021-2026) & (K Dose)
Figure 44. iPSC-Derived Natural Killer Cells Consumed in Infectious Disease Research
Figure 45. Global iPSC-Derived Natural Killer Cells Market: Infectious Disease Research (2021-2026) & (K Dose)
Figure 46. iPSC-Derived Natural Killer Cells Consumed in Drug Screening and Mechanism Studies
Figure 47. Global iPSC-Derived Natural Killer Cells Market: Drug Screening and Mechanism Studies (2021-2026) & (K Dose)
Figure 48. iPSC-Derived Natural Killer Cells Consumed in Cell Therapy Process Development
Figure 49. Global iPSC-Derived Natural Killer Cells Market: Cell Therapy Process Development (2021-2026) & (K Dose)
Figure 50. iPSC-Derived Natural Killer Cells Consumed in Other Applications
Figure 51. Global iPSC-Derived Natural Killer Cells Market: Other Applications (2021-2026) & (K Dose)
Figure 52. Global iPSC-Derived Natural Killer Cells Sale Market Share by Application (2025)
Figure 53. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application in 2025
Figure 54. iPSC-Derived Natural Killer Cells Sales by Company in 2025 (K Dose)
Figure 55. Global iPSC-Derived Natural Killer Cells Sales Market Share by Company in 2025
Figure 56. iPSC-Derived Natural Killer Cells Revenue by Company in 2025 ($ millions)
Figure 57. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Company in 2025
Figure 58. Global iPSC-Derived Natural Killer Cells Sales Market Share by Geographic Region (2021-2026)
Figure 59. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Geographic Region in 2025
Figure 60. Americas iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 61. Americas iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 62. APAC iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 63. APAC iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 64. Europe iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 65. Europe iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 66. Middle East & Africa iPSC-Derived Natural Killer Cells Sales 2021-2026 (K Dose)
Figure 67. Middle East & Africa iPSC-Derived Natural Killer Cells Revenue 2021-2026 ($ millions)
Figure 68. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Country in 2025
Figure 69. Americas iPSC-Derived Natural Killer Cells Revenue Market Share by Country (2021-2026)
Figure 70. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 71. Americas iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 72. United States iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 73. Canada iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 74. Mexico iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 75. Brazil iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 76. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Region in 2025
Figure 77. APAC iPSC-Derived Natural Killer Cells Revenue Market Share by Region (2021-2026)
Figure 78. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 79. APAC iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 80. China iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 81. Japan iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 82. South Korea iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 83. Southeast Asia iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 84. India iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 85. Australia iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 86. China Taiwan iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 87. Europe iPSC-Derived Natural Killer Cells Sales Market Share by Country in 2025
Figure 88. Europe iPSC-Derived Natural Killer Cells Revenue Market Share by Country (2021-2026)
Figure 89. Europe iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 90. Europe iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 91. Germany iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 92. France iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 93. UK iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 94. Italy iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 95. Russia iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 96. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Market Share by Country (2021-2026)
Figure 97. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Market Share by Type (2021-2026)
Figure 98. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Market Share by Application (2021-2026)
Figure 99. Egypt iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 100. South Africa iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 101. Israel iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 102. Turkey iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 103. GCC Countries iPSC-Derived Natural Killer Cells Revenue Growth 2021-2026 ($ millions)
Figure 104. Manufacturing Cost Structure Analysis of iPSC-Derived Natural Killer Cells in 2026
Figure 105. Manufacturing Process Analysis of iPSC-Derived Natural Killer Cells
Figure 106. Industry Chain Structure of iPSC-Derived Natural Killer Cells
Figure 107. Channels of Distribution
Figure 108. Global iPSC-Derived Natural Killer Cells Sales Market Forecast by Region (2027-2032)
Figure 109. Global iPSC-Derived Natural Killer Cells Revenue Market Share Forecast by Region (2027-2032)
Figure 110. Global iPSC-Derived Natural Killer Cells Sales Market Share Forecast by Type (2027-2032)
Figure 111. Global iPSC-Derived Natural Killer Cells Revenue Market Share Forecast by Type (2027-2032)
Figure 112. Global iPSC-Derived Natural Killer Cells Sales Market Share Forecast by Application (2027-2032)
Figure 113. Global iPSC-Derived Natural Killer Cells Revenue Market Share Forecast by Application (2027-2032)
